Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by CytRx Corporation
CytRx Corporation Relaunches as LadRx Corporation
September 23, 2022
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
European Patent Office Awards CytRx Key Patent
September 07, 2022
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors
August 09, 2022
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock
May 19, 2022
From
CYTRX CORPORATION
Via
Business Wire
Tickers
CYTR
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
May 17, 2022
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Partners with Oncology Development Expert to Advance LADR Platform
April 20, 2022
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress
March 21, 2022
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C
February 24, 2022
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C
February 14, 2022
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx to Hold Town Hall for Stockholders on Thursday, January 20th
January 18, 2022
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx to Participate in the H.C. Wainwright BioConnect Virtual Conference
January 07, 2022
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer
January 03, 2022
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer
December 21, 2021
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Provides a Bold Vision on Centurion BioPharma's Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada
November 30, 2021
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Comments on Quarterly Results and Recent Strategic Initiatives
November 12, 2021
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Announces Centurion BioPharma Has Been Invited to Present Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada
November 09, 2021
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C
November 02, 2021
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment
October 14, 2021
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx to Present at Upcoming Virtual LD Micro Conference
October 05, 2021
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C
August 24, 2021
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
ORPH
CytRx Comments on Quarterly Results and Recent Strategic Initiatives
August 12, 2021
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders
July 29, 2021
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022
July 29, 2021
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Corporation Announces Closing of $10 Million Offering to Healthcare-Focused Institutional Investor
July 16, 2021
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Investor
July 13, 2021
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Comments on Orphazyme’s Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C
June 30, 2021
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Notes Orphazyme’s Regulatory Update from the FDA on Arimoclomol for Niemann-Pick Disease Type C
June 18, 2021
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx to Present at Upcoming Investor Conferences
June 02, 2021
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
CytRx Comments on Quarterly Results and Year-to-Date Progress
May 13, 2021
From
CytRx Corporation
Via
Business Wire
Tickers
CYTR
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.